The discovery could lead to targeted therapy in triple negative breast cancer patients.
Basal-like breast cancer (BLBC), more commonly known as triple-negative breast cancer, is a deadly disease with poor prognosis. Highly prevelant among younger and African-American women, the disease is associated with extensive metastasis early in the disease. Now, scientists at the Boston University School of Medicine and the University of Cyprus have identified a biomarker, a receptor called IL13RA2; high levels of expression of this receptor could indicate worse progression-free survival. Women who had high expression of IL13RA2 also presented with increased lung metastases.
In their study published in Breast Cancer Research the authors show that depletion of this receptor in metastatic breast cancer cells reduced growth of the primary tumor and also had a significant impact on preventing lung metastases. A genomewide transcription analysis showed that knowckdown of IL13AR2 and treatment of breast cancer cells with IL2 resulted in a STAT6-dependent TP63 signaling, which could be responsible for the reduced lung metastases of these cancerous cells.
"This discovery offers a glimmer of hope for patients stricken with BLBC. Personalized cancer therapies could be developed by targeting breast cancer cells that express copious levels of IL13RA2," explained corresponding author Sam Thiagalingam, PhD, in an interview. Considering that IL13RA2 is also expressed in other deadly cancers such as pancreatic, brain, and ovarian cancer, these results have a much wider implication.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More